Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
43.80    0.00 (0.00%)
Bid:
42.80
Ask:
44.80
Spread: 2.00 (4.673%)
Market Cap: £68.37m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Statement re Offer for Subscription

10 Jan 2022 12:43

RNS Number : 9606X
Maven Income and Growth VCT 3 PLC
10 January 2022
 

Maven Income and Growth VCT 3 PLC and Maven Income and Growth VCT 4 PLC (the Companies)

 

Offers for Subscription - Early Investment Incentive

 

10 January 2022

 

On 20 September 2021, the Companies published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription of new Ordinary Shares of 10p each (together the "Offers" and each an "Offer").

 

In the Prospectus, it was stated that all valid applications that were received (together with their relevant application monies) by the deadline of 12.00 noon on 28 January 2022 would be eligible to receive an Early Investment Incentive discount under the Offers. Existing Shareholders (and their spouses or partners) in any of the Maven VCTs, including the Companies, at the time the application was received would benefit from an enhanced rate of discount in recognition of their continued support for the Maven VCTs. The levels of discount to be applied would be:

 

· 1.5% of the application amount for Existing Shareholders; and

· 1.25% of the application amount for New Investors.

 

It was also stated that each Company could, in consultation with Maven Capital Partners UK LLP (Maven) and in their absolute discretion, extend the deadline by which applications must be received to be eligible for the Early Investment Incentive under its Offer.

 

The Board of each Company confirms that the deadline by which applications must be received to be eligible for the Early Investment Incentive under their Company's respective Offer has been extended until close of business on Wednesday 2 February 2022. Furthermore, it is anticipated that both Companies will make initial allotments of new Ordinary Shares under their respective Offers as soon as practicable after that date.

 

Further information

 

Any enquiries in respect of the Offers, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

 

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

 

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Downloadable versions of the Prospectus documents are available from the Maven website at: www.mavencp.com/vctoffer.

Maven Capital Partners UK LLPSecretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFLFSFLIIILIF
Date   Source Headline
11th Mar 202211:35 amRNSIssue of Equity - Dividend Investment Scheme
10th Mar 202211:30 amRNSIssue of Equity
10th Mar 202211:20 amRNSStatement re Dividend Investment Scheme
7th Mar 20226:32 pmRNSAnnual Financial Report
22nd Feb 20222:27 pmRNSTransaction in Own Shares
18th Feb 20225:48 pmRNSIssue of Equity - Replacement Announcement
7th Feb 20221:53 pmRNSDirector/PDMR Shareholding
7th Feb 20221:52 pmRNSDirector/PDMR Shareholding
7th Feb 20221:50 pmRNSDirector/PDMR Shareholding
7th Feb 20221:48 pmRNSDirector/PDMR Shareholding
7th Feb 20221:47 pmRNSDirector/PDMR Shareholding
7th Feb 20221:46 pmRNSDirector/PDMR Shareholding
7th Feb 202210:50 amRNSIssue of Equity
4th Feb 20229:45 amRNSStatement re NAV and Final Dividend
31st Jan 20224:25 pmRNSStatement re Offer for Subscription
10th Jan 202212:43 pmRNSStatement re Offer for Subscription
5th Jan 202210:35 amRNSDividend Declaration
24th Nov 20214:45 pmRNSTransaction in Own Shares
29th Oct 202112:44 pmRNSNet Asset Value(s)
20th Oct 20214:46 pmRNSResult of General Meeting
20th Sep 20215:21 pmRNSPublication of a Prospectus
20th Sep 20214:57 pmRNSStatement re Change of Registrar
10th Sep 202112:34 pmRNSIssue of Equity
7th Sep 20213:08 pmRNSStatement re Dividend Investment Scheme
16th Aug 20214:08 pmRNSTransaction in Own Shares
13th Aug 20212:13 pmRNSHalf-year Report
5th Aug 20214:39 pmRNSTransaction in Own Shares
3rd Aug 202111:31 amRNSStatement re NAV and Interim Dividend
16th Jun 20213:16 pmRNSStatement re Offer for Subscription
16th Apr 202110:25 amRNSIssue of Equity
15th Apr 20214:30 pmRNSTransaction in Own Shares
13th Apr 20212:22 pmRNSStatement re Dividend Investment Scheme
12th Apr 20219:00 amRNSNet Asset Value(s)
7th Apr 202112:28 pmRNSResult of AGM
5th Mar 20214:39 pmRNSFinal Results
29th Jan 20212:55 pmRNSTransaction in Own Shares
22nd Jan 20213:17 pmRNSNAV and Proposed Final Dividend
17th Nov 20204:29 pmRNSTransaction in Own Shares
16th Nov 20204:55 pmRNSTransaction in Own Shares
11th Nov 20204:58 pmRNSNet Asset Value(s)
28th Aug 202010:28 amRNSIssue of Equity
26th Aug 20205:23 pmRNSTransaction in Own Shares
21st Aug 20204:10 pmRNSStatement re NAV and DIS
29th Jul 20204:45 pmRNSTransaction in Own Shares
28th Jul 20204:44 pmRNSTransaction in Own Shares
24th Jul 20203:23 pmRNSHalf-year Report
9th Jul 202010:00 amRNSIssue of Equity
29th Jun 20205:25 pmRNSStatement re NAV and Interim Dividend
8th Jun 20209:33 amRNSAllotment Update
15th May 20204:55 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.